Is NewcelX AG halal to invest in?

According to Musaffa's Shariah screening methodology, NewcelX AG (NCEL) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is NewcelX AG a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes NewcelX AG using these criteria to determine its compliance status.

Can Muslims buy shares of NewcelX AG?

Muslim investors may consider investing in NewcelX AG if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is NewcelX AG classified as NOT HALAL?

Musaffa determines the Shariah status of NewcelX AG by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for NewcelX AG updated?

The Shariah compliance status of NewcelX AG may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like NewcelX AG become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of NewcelX AG?

You can check the latest Shariah compliance status of NewcelX AG on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NCEL Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 11, 2026

Report Source: 2025 2nd Quarter Report

NewcelX AG. Stock Analysis NCEL

United States Health Care Nano Cap Report: Q2, 2025

NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The firm offers products like Quilience, which is a clinical-stage pharmaceutical compound. The company aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The firm also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The firm is a publicly traded company, listing on the NASDAQ.

Key Statistics of NewcelX AG (NCEL)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$3.21$3.54

Today's Open

$3.37

Volume

13.29K

P/E Ratio (TTM)

52 Week Range

$1.83$30.80

Market Cap

19.19M

Avg. Volume

71.09K

Dividend Yield

Financial Metrics & Statements of NewcelX AG (NCEL)

FAQ's for NewcelX AG (NCEL)

According to Musaffa’s Shariah screening methodology, NewcelX AG (NCEL) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.